Article Information
History
- October 30, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Mao Hu, BS1,
- Hui Lee Wong, PhD, MSc2,
- Yuhui Feng, MS1,
- Patricia C. Lloyd, PhD, ScM2,
- Elizabeth R. Smith, BS1,
- Kandace L. Amend, PhD3,
- Annemarie Kline, MS4,
- Daniel C. Beachler, PhD, MPH5,
- Joann F. Gruber, PhD2,
- Mahasweta Mitra, MPH1,
- John D. Seeger, DrPH, PharmD3,
- Charlalynn Harris, MPH, PhD4,
- Alex Secora, PhD6,
- Joyce Obidi, PhD2,
- Jing Wang, BA1,
- Jennifer Song, MA, MURP3,
- Cheryl N. McMahill-Walraven4,
- Christian Reich, MD, PhD6,
- Rowan McEvoy, BS1,
- Rose Do, MD1,
- Yoganand Chillarige, MPA1,
- Robin Clifford, MS, BS3,
- Danielle D Cooper4,
- Azadeh Shoaibi, PhD, MHS2,
- Richard Forshee, PhD2 and
- Steven A. Anderson, PhD, MPP2,*
- 1Acumen LLC, Burlingame, CA, USA
- 2US Food and Drug Administration, Silver Spring, MD, USA
- 3Optum Epidemiology, Boston, MA, USA
- 4HealthCore, Inc, Wilmington, DE, USA
- 5CVS Health Clinical Trial Services, Blue Bell, PA, USA
- 6IQVIA, Falls Church, VA, USA
- ↵*Corresponding Author:
Steven A. Anderson, Ph.D., M.P.P., Director, Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, U. S. Food & Drug Administration 10903 New Hampshire Ave., Silver Spring, MD 20993, email: steven.anderson{at}fda.hhs.gov
Posted October 30, 2022.
Results of safety monitoring of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in U.S. children aged 5-17 years
